AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Armata Pharmaceuticals Secures $3.7 Million in Non-Dilutive Funding for Phase 3 Development
PUBLIC · ARMPSep 23, 2026•about 16 hours ago
Amount Raised
$3.7 Million
Round Type
Funding Round
Los AngelesBiotechnology
Investors
U.S. Department Of War
Description
On September 23, 2026, Armata Pharmaceuticals announced the receipt of $3.7 million in additional non-dilutive funding from the U.S. Department of War. This funding will support activities related to the Phase 3 development program for its product candidate AP-SA02. The product is aimed at treating complicated bacteremia caused by Staphylococcus aureus infections
Company Information
Company
Armata Pharmaceuticals
Location
Los Angeles, California, United States
About
Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.
Fundz sees it the moment Armata Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Los AngelesBiotechnology